Table 2

The ACPA antibodies as predictors of radiographic progression, results from univariate and multivariate logistic regression analyses

Univariate analysesMultivariate model with anti-MCVMultivariate model with anti-CCP
OR (95% CI)p ValueOR (95% CI)p ValueOR (95% CI)p Value
Antibodies:
Progression in total SHS
    Anti-MCV+7.3 (3.2 to 16.5)<0.014.1 (1.4 to 11.9)<0.01
    Anti-CCP+5.7 (2.6 to 12.5)<0.013.1 (1.1 to 9.2)<0.01
Other variables in analyses:
    RF+5.2 (2.4 to 11.3)<0.012.4 (0.9 to 6.4)0.082.3 (0.9 to 6.1)0.09
    PTPN22 1858T+1.6 (0.7 to 3.6)0.241.1 (0.4 to 3.1)0.831.1 (0.4 to 3.0)0.80
    SE+2.3 (0.9 to 5.7)0.070.9 (0.3 to 2.7)0.850.9 (1.1 to 9.2)0.80
    ESR1.04 (1.02 to 1.07)<0.011.03 (0.99 to 1.06)0.071.03 (1.00 to 1.06)0.03
    Female gender2.6 (1.1 to 5.9)0.033.9 (1.3 to 11.3)0.013.5 (1.2 to 9.9)0.02
    Age1.2 (0.9 to 1.1)0.801.0 (1.0 to 1.1)0.990.98 (0.95 to 1.02)0.39
Progression in erosion score
    Anti-MCV+6.2 (2.7 to 14.1)<0.01
    Anti-CCP+4.6 (2.1 to 10.0)<0.01
Progression in JSN score
    Anti-MCV+2.8 (1.4 to 5.6)<0.01
    Anti-CCP+2.6 (1.3 to 4.9)<0.01
  • ACPA, anti-citrullinated peptide antibody; CCP, cyclic citrullinated peptide; ESR, erythrocyte sedimentation rate; JSN, joint space narrowing; MCV, mutated citrullinated vimentin; OR, odds ratio; PTPN22, protein tyrosine phosphatase, non-receptor type 22; RF, rheumatoid factor; SE, shared epitope; SHS, van der Heijde modified Sharp score.